Articles Archives
Articles
07/21/2026
What it Takes to Launch a Modern Supply Chain Operation
As we move closer to launch on August 17, 2026, the Santa Ana facility is transitioning from a construction project to an operational asset representing a milestone that required months of coordinated work across engineering, facilities, operations, product, quality, IT, and supply chain teams. A facility may represent the physical footprint, but true operational readiness is measured by systems, processes, people, equipment, compliance, and execution.
Articles
07/20/2026
Expert Q&A: Going Deeper on Early Supply Chain Strategy for CGT Programs
Advanced therapy developers rarely have the luxury of perfect timing. Programs are often moving toward the next milestone with limited resources, data that’s evolving in real time, and pressure to make decisions before every variable is fully understood. That reality was at the center of the recent webinar, “Prevent Advanced Therapy Program Delays with Early Supply Chain Strategy,” where panelists discussed how early decisions around logistics, cryopreservation, packaging, site readiness, documentation, and cross-functional alignment can influence everything downstream.
Articles
07/06/2026
Building the Foundation: Our New Global Supply Chain Center in Santa Ana, California
End-to-end supply chain execution is a competitive advantage. Speed, reliability, and adaptability define how businesses deliver for customers. That’s why we’ve invested in a consolidated 86,500‑square‑foot Global Supply Chain Center (GSCC) in Santa Ana, California, a strategic step forward in strengthening the backbone of our global operations.
Articles
06/17/2026
New ISCT Thought Leadership Explores Why Growth in CGT Demands a Different Operating Model
The way the industry thinks about scale is starting to shift. For decades, growth in biopharmaceutical development has followed a familiar pattern. As programs advance, manufacturing expands and throughput increases, allowing therapies to move from limited, early-phase clinical trial settings into broader patient populations. A new article from Cryoport Systems published through the International Society for Cell & Gene Therapy (ISCT) explores how scale behaves differently in advanced therapies and why the industry may need to rethink the operating models used to support it.
Articles
05/26/2026
Cryoport Systems with ISCT on Why Early-Phase Development is Starting to Strain
As advanced therapy programs move faster toward first-in-human (FIH), the pressure isn’t just showing up at commercial scale. It’s appearing much earlier than many teams expect. A recent article Cryoport Systems published with ISCT takes a closer look at that shift, highlighting why execution (not feasibility) is increasingly becoming the constraint in early development.
Articles
05/26/2026
Matthew Plaud on Building Supply Chains that Actually Scale
In a recent conversation with Contract Pharma, Matthew Plaud, COO of IntegriCell® at Cryoport Systems, discussed where advanced therapy supply chains stand today, and where they start to strain as programs move toward commercialization.
Articles
03/18/2026
Cryoport Systems Honored at the Asia Pacific Biopharma Excellence Awards
Cryoport Systems is pleased to announce that we have been awarded Best Logistics & Supply Chain Management Supplier – Digital Technology & Software at the Asia Pacific Biopharma Excellence Awards 2026, held March 11 in Singapore. This recognition reflects both the progress of our organization and the growing importance of dependable, technology-driven support in the development and delivery of advanced therapies across the region.
Articles
11/17/2025
Cryoport Systems Named Finalist in Four Categories at Asia-Pacific Biopharma Excellence Awards 2026
Cryoport Systems has been named a finalist in four categories for the upcoming Asia-Pacific Biopharma Excellence Awards 2026. These nominations reflect our unwavering commitment to innovation and excellence in supporting the global biopharma community.
Articles
10/30/2025